TABLE 2.
Clinical Trials of Jakinibs with COVID-19 patients.
| Jakinibs | Combination | Clinical Trial a b | ||||
|---|---|---|---|---|---|---|
| Clinical trial Identifier | Location | Start Date | Phase | outcomes | ||
| Baricitinib | NCT04390464 | United Kingdom | May 8, 2020 | 4 | Unknown | |
| NCT04421027 | USA | June 12, 2020 | 3 | Completed | ||
| NCT05056558 | Bangladesh | October 2021 | 3 | Not yet recruiting | ||
| NCT05074420 | USA | December 21, 2021 | 3 | Recruiting | ||
| NCT04340232 | USA | April 9, 2020 | 2/3 | Withdrawn (Could not make FDA-required changes) | ||
| NCT04358614 | Italy | March 16, 2020 | 2/3 | Completed | ||
| NCT04891133 | Austria | May 18, 2021 | 2/3 | Recruiting | ||
| NCT04381936 | Multinational | May 11, 2020 | 2/3 | Recruiting | ||
| NCT04393051 | Italy | May 20, 2020 | 2 | Unknown | ||
| NCT04346147 | Spain | May 7, 2020 | 2 | Active, not recruiting | ||
| NCT04399798 | Italy | May 22, 2020 | 2 | Unknown | ||
| Remdesivir | NCT04970719 | Bangladesh | July 10, 2021 | 3 | Recruiting | |
| NCT04693026 | Bangladesh | September 10, 2020 | 3 | Recruiting | ||
| NCT04401579 | USA | May 8, 2020 | 3 | Completed | ||
| NCT04640168 | USA | December 2, 2020 | 3 | Completed | ||
| NCT04321993 | Canada | April 17, 2020 | 2 | Recruiting | ||
| Dexamethasone, Ramdesivir | NCT04832880 | Italy | April 6, 2021 | 3 | Not yet recruiting | |
| Lopinavir/Ritonavir | NCT04320277 | Italy | May 16, 2020 | 2/3 | Unknown | |
| Dexamethasone | NCT04890626 | Spain | May 18, 2021 | 3 | Recruiting | |
| Olokizumab | NCT05187793 | Russian Federation | July 8, 2021 | 3 | Recruiting | |
| Hydroxychloroquine | NCT04373044 | USA | May 4, 2020 | 2 | Terminated (The study was terminated after the release of results of ACTT-2 (NCT04401579). | |
| Tocilizumab | NCT05082714 | Greece | October 19, 2021 | NA | Recruiting | |
| Tocilizumab, inhaled DNase | NCT05279391 | Greece | April 20, 2021 | NA | Recruiting | |
| Ruxolitinib | NCT04377620 | USA | May 24, 2020 | 3 | Terminated (Study terminated by sponsor) | |
| NCT04362137 | USA | May 2, 2020 | 3 | Completed | ||
| NCT04348071 | USA | July 2021 | 2/3 | Withdrawn (Could not make FDA-required changes) | ||
| NCT04477993 | Brazil | August 14, 2020 | 2/3 | Terminated (Low accrual) | ||
| NCT04354714 | USA | June 30, 2020 | 2 | Withdrawn (Could not make FDA-required changes) | ||
| NCT04414098 | USA | June 1, 2020 | 2 | Unknown | ||
| NCT04403243 | Russian Federation | May 8, 2020 | 2 | Completed | ||
| NCT04338958 | Germany | April 22, 2020 | 2 | Completed | ||
| NCT04334044 | Mexico | September 1, 2020 | 1/2 | Completed | ||
| NCT04359290 | Germany | July 1, 2020 | 2 | Completed | ||
| NCT04581954 | UK | October 2, 2020 | 1/2 | Recruiting | ||
| NCT04331665 | Canada | May 21, 2020 | NA | Terminated | ||
| Tocilizumab, Anakinra | NCT04424056 | France | September 1, 2020 | 3 | Unknown | |
| Anakinra | NCT04366232 | France | August 19, 2020 | 2 | Terminated (investigator decision) | |
| Therapeutic Plasma Exchange | NCT04374149 | USA | April 30, 2020 | 2 | Completed | |
| Simvastatin | NCT04348695 | Spain | April 12, 2020 | 2 | Completed | |
| Tofacitinib | NCT04412252 | USA | June 2, 2020 | 2 | Withdrawn by sponsor | |
| NCT04415151 | USA | October 14, 2020 | 2 | Terminated (enrolment issues) | ||
| NCT04750317 | Russian Federation | May 11, 2020 | 2 | Completed | ||
| NCT04469114 | Brazil | September 16, 2020 | 3 | Completed | ||
| Hydroxychloroquine | NCT04390061 | Italy | June 2020 | 2 | Unknown | |
| mRNA vaccine | NCT05080218 | USA | November 15, 2021 | 4 | Recruiting | |
| Pacritinib | NCT04404361 | USA | May 22, 2020 | 3 | Terminated | |
| Nezulcitinib | NCT04350736 | United Kingdom | April 23, 2020 | 1 | Completed | |
| NCT05091723 | USA | October 13, 2021 | 1 | Completed | ||
| NCT04402866 | Multinational | June 24, 2020 | 2 | Completed | ||
a
Information as of December 2022.
b
Information assessed from ClinicalTrials.gov.